A Phase 2/3 interventional study of Faecal microbiota transplantation and Placebo in Liver Cirrhosis, sponsored by University of Aarhus. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-24.
Sponsored by University of Aarhus · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Liver Cirrhosis with a site in Denmark — 6 open to participants now, 7 under way, 1 of them phase 3. Liver Cirrhosis · Denmark.
Among the 35 studies in Liver Cirrhosis with a site in Denmark, this one is the 5th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2021, is the only one in phase 2/3, and was the 29th registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →6 of the 35 studies in Liver Cirrhosis with a site in Denmark are open now. Recruiting first, the newest first:
Zealand University Hospital · Sites in Denmark
Ages 18–110
Maja Thiele · Sites in Denmark
Ages 30–75
Esbjerg Hospital - University Hospital of Southern Denmark · Sites in Denmark
Ages 18+
Esbjerg Hospital - University Hospital of Southern Denmark · Sites in Denmark
Ages 18–90 · Healthy volunteers
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 3 · Phase 4 2
First in 2000; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 220 is above the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 70 across the 19 interventional studies, 95 across the 16 observational. Of the 23 that completed or were terminated, 2 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 35 have an industry lead sponsor. The 10 most frequent:
University of Aarhus is the lead sponsor of 1,303 studies on the registry; 190 are open to participants now.
University of Aarhus has 7 studies filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
2 of the studies in Liver Cirrhosis with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05433948Esbjerg Hospital - University Hospital of Southern DenmarkDiagnosing Minimal Hepatic Encephalopathy | 2026-12-01 |
| NCT05431946Esbjerg Hospital - University Hospital of Southern DenmarkPalliative Care for Patients With Liver Cirrhosis | 2027-08-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies in Liver Cirrhosis with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose is to investigate the effect of faecal microbiota transplantation (FMT) on complications, progression, and mortality of patients with liver cirrhosis. Further, the investigators want to examine the impact of FMT on the gut microbiota, gut barrier function, systemic inflammation, and immune function.
Patients with liver disease have a disturbed gut microbiota. This is often associated with disease progression and development of complications, so-called episodes of decompensation. In this trial, we will change the microbiota of these patients by transferring a healthy microbiota through faeces from a healthy donor, a procedure known as faecal microbiota transplantation (FMT). We will examine the effect of FMT on the prognosis and disease progression of the patients. Further, we will examine the mechanistic effects of FMT. We will at random divide 220 patients admitted with decompensation of liver cirrhosis evenly into two groups. One group will receive FMT and the other group will receive placebo. After the treatment, we will follow the patients for one year and examine disease progression as well as changes in their gut microbiota, gut barrier, and immune function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patients will receive three applications of FMT consisting of 50 g cryopreserved, homogenized faeces from healthy donors. The faecal material will be dispensed into double-coated, acid-resistant enterocapsules or cryobags. Faeces will be screened according to international guidelines.
Biological: Faecal microbiota transplantation
The placebo products is produced from a suspension of glycerol, saline and food colouring and cannot be distinguished from the active FMT products.
Biological: Placebo
All participant will receive three applications of either FMT or placebo and afterwards followed for 1 year.
Also known as: FMT
Placebo
Time to death or new episode of acute decompensation requiring intervention in FMT versus placebo-treated patients.
Using data from the patient journals, we will be able to examine the exact time to event in each of the patients. To compare the two groups, hazard ratios will be calculated.
Time frame: 1 year
Time to death or new episode of acute decompensation requiring intervention in FMT versus placebo-treated patients at 3 months and 6 months of follow-up.
Using data from the patient journals, we will be able to examine the exact time to event in each of the patients. To compare the two groups, hazard ratios will be calculated.
Time frame: 3 months, 6 months
Number of new decompensations and deaths during follow-up in the FMT versus the placebo-treated patients.
Incidence rates will be compared between the groups.
Time frame: 1 year
Time to death in FMT versus placebo-treated patients. -treated patients at 3 months and 6 months of follow-up.
Using data from the patient journals, we will be able to examine the exact time to event in each of the patients. To compare the two groups, hazard ratios will be calculated.
Time frame: 1 year, 6 months, 3 months
Change in gut microbiota beta-diversity (Bray-Curtis index) during one year in FMT versus placebo-treated patients by shotgun metagenomic sequencing.
In stool and saliva samples collected before and at 5 time points following the intervention, we will measure the gut microbiota composition.
Time frame: 1 year, 6 months, 3 months
Change in plasma concentration of gut translocation markers; lipopolysaccharide binding protein, soluble CD14, fatty acid binding protein 1 during one year in FMT versus placebo-treated patients by ELISA.
In blood samples collected at baseline and at follow-up visits, we will measure these plasma proteins by ELISA.
Time frame: 1 year, 6 months, 3 months
Change in plasma and stool concentration of pro- and antiinflammatory cytokines; IL-6, IL-1beta, TNF-alpha, IL-8, IL-10 in response to the intervention by luminex.
In blood and stool samples collected at baseline and at follow-up visits, we will measure these plasma proteins by luminex.
Time frame: 1 year, 6 months, 3 months
Change in disease severity in FMT- versus placebo-treated patients.
The disease severity will be measured with Model for Endstage Liver Disease (MELD) (range 6-40). A high score reflects poor prognosis.
Time frame: 3 months, 6 months, 1 year.
Change in disease severity in FMT- versus placebo-treated patients.
The disease severity will be measured with Child-Pugh score (range 5-15). A high score reflects poor prognosis.
Time frame: 3 months, 6 months, 1 year.
Change in disease severity in FMT- versus placebo-treated patients.
The disease severity will be measured with CliF-C Acute decompensation scores (range 0-18). A high score reflects poor prognosis.
Time frame: 3 months, 6 months, 1 year.
Change in metabolic liver function in FMT- versus placebo-treated patients.
The metabolic liver function will be measured by the aminopyrine breath test
Time frame: 3 months, 6 months, 1 year.
Change in liver stiffness in FMT- versus placebo-treated patients.
Liver stiffness will be measured by liver elastography.
Time frame: 3 months, 6 months, 1 year.
Change in the Liver Frailty Index in FMT- versus placebo-treated patients.
The Liver Frailty index (grip strength, chair stands, and balance testing) will be calculated and the index will be compared between the treatment groups. A higher LFI indicates more frailty.
Time frame: 3 months, 6 months, 1 year.
Change in body composition in FMT- versus placebo-treated patients.
Body composition will be measured by bioimpedance.
Time frame: 3 months, 6 months, 1 year.
Change in cognitive function as measured by continuous reaction time in FMT- versus placebo-treated patients.
The cognitive function will be measured with continuous reaction time.
Time frame: 3 months, 6 months, 1 year.
Change in cognitive function in FMT- versus placebo-treated patients.
The cognitive function will be measured with the portosystemic encephalopathy syndrome test.
Time frame: 3 months, 6 months, 1 year.
Change in quality adjusted life years (QALY´s) to evalute health care related costs in FMT- versus placebo-treated patients
By using the quality-of-life questionnaire (EQ-5D-5L) a single index will be calculated and used to calculate QALY's.
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2021 (actual). Primary completion is estimated for May 2026, 58 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.